Related Experiment Videos
Hydralazine therapy in chronic congestive heart failure. Sustained central and regional hemodynamic responses
Insights
Long-term hydralazine therapy improved cardiac output and blood flow in patients with idiopathic dilated cardiomyopathy. Hemodynamic tolerance did not develop, indicating sustained benefits for chronic heart failure management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Idiopathic dilated cardiomyopathy (IDC) is a severe condition often leading to chronic heart failure.
- Management of IDC focuses on improving hemodynamic function and patient outcomes.
Purpose of the Study:
- To evaluate the long-term effects of hydralazine on central and regional hemodynamic parameters in patients with IDC.
- To assess the development of hemodynamic tolerance to oral hydralazine therapy.
Main Methods:
- A randomized, placebo-controlled trial involving 20 patients with New York Heart Association (NYHA) classes III and IV IDC.
- Patients received either placebo or hydralazine (100 mg orally every eight hours) for three months.
- Central and regional hemodynamic parameters, including cardiac index, renal blood flow, and limb blood flow, were measured at baseline and after three months.
Main Results:
- Hydralazine therapy significantly increased cardiac index (25%), renal blood flow (26%), and limb blood flow (35%) compared to placebo and baseline values (p < 0.05).
- No significant changes in hemodynamic parameters were observed in the placebo group.
- The majority of patients did not develop central or regional hemodynamic tolerance to hydralazine over the three-month period.
Conclusions:
- Long-term (three months) oral hydralazine therapy elicits a favorable circulatory response in patients with chronic congestive heart failure due to IDC.
- Sustained hemodynamic benefits suggest hydralazine is a viable treatment option, as tolerance did not develop in most patients.
Abstract:
Central and regional hemodynamic parameters were evaluated at baseline and following three months of placebo or hydralazine therapy (100 mg orally every eight hours) in 20 patients with idiopathic dilated cardiomyopathy. Both control (placebo) and hydralazine groups were comparable with respect to functional classification (New York Heart Association classes III and IV) and baseline hemodynamic variables. In the hydralazine group, cardiac index increased 25 percent (2.4 +/- 0.4 to 3.0 +/- 0.5 liters/minute/m2), renal blood flow increased 26 percent (648 +/- 199 to 815 +/- 229 ml/minute), and limb blood flow was augmented by 35 percent (6.8 +/- 3.0 to 9.2 +/- 4.6 ml/dl/minute) with long-term therapy. These changes were significant (all p less than 0.05) when compared with both baseline values and values in the control group. Both central and regional hemodynamic parameters remained unaltered in the control group. Long-term hydralazine therapy (three months) elicited a favorable circulatory response in this group of patients with chronic congestive heart failure. Central or regional hemodynamic tolerance to oral hydralazine failed to develop in the majority of patients.